iBio inc. (NYSE:IBIO) rose to popularity amongst the investor community as they announced their intentions to develop a COVID-19 vaccine. The stock is currently trading 586% higher since the beginning of 2020. However since July, iBio stock has been on a downward slope which has since found a new equilibrium at $2. The initial announcement of […]
Category Archives: Pharmaceutical and Biotechnological Stocks
SRNE stock forecast indicates a bullish 2021 – is it real or COVID-19 hype?
Sorrento Therapeutics (NASDAQ: SRNE) was lacking direction as short-sellers brought down the stock after most positive announcements. However, the green light from the FDA allows the bulls to lay down the trackwork. The clear path is promising, but the volatility is making it difficult for investors to enter. Today’s article looks to make sense of […]
CVS stock forecast 2021 – will the healthcare giant bounce back?
CVS Health (NASDAQ: CVS) stock has been going on a rollercoaster ride in 2020 so far. The start of the year was promising as the healthcare giant hit 52-week highs. Unfortunately, COVID-19 sent CVS spiraling down. Investors are currently unsure what is in store for CVS come 2021 and beyond. Especially, as the CVS stock […]
Will the Teva stock recover after a 10% sell-off?
Will Teva stock recover from the recent bloodbath? It is the big question institutions and retail investors are asking. On one end, investors believe the lawsuit and stagnating financials will cripple Teva. Conversely, the bullish hedge funds argue that Teva holds value in the long-term. Thus, today’s article will breakdown the recent sell-off, which institutions […]
FDA gives Sorrento Therapeutics the green light to begin Phase I COVID-19 trials – Should you short?
Sorrento Therapeutics (NASDAQ: SRNE) is putting on a volatility show this week. The bulls were leading the charge at the start of the week but took a big rest on Wednesday, which saw SRNE pullback by 12%. All bullish hope seemed lost. However, today the FDA gave Sorrento the green light to begin phase I […]
INO surges 10% pre-market – here’s what you need to know
Inovio (NASDAQ:INO) is set to open 10% higher this morning after the promising address by CEO & President Dr. Joseph Kim on the H.C Wainwright 22nd Annual Investment Conference. Dr. Kim advised that the initiation of Phase 2 trials for their COVID-19 vaccine INO-4800 is on track to commence later this month. The CEO also […]
Biomerica set to release earnings this Friday – here’s what you need to know.
Biomerica (NASDAQ:BMRA) is set to release Q2 earnings this Friday, with experts forecasting an expected EPS of -$0.05. This would mark a 37% improvement for Q2 Earnings Year on Year. The medical diagnostic manufacturer has thrived on the opportunity this year to develop a viable COVID-19 test. Biomerica’s rapid COVID-19 test is marketed produce results […]
Fluidigm soars 25% on COVID-19 FDA approval – here’s what you need to know
Fluidigm Corporation (NASDAQ: FLDM) just became a bull-market magnet as its COVID-19 saliva kit received FDA approval. Optimism is high in pre-market trading as some bullish investors believe this is news to send FLDM soaring. However, the bears are screaming that a pump and dump is coming at the bell. The division in sentiment causes […]
Johnson & Johnson set to acquire Momenta Pharmaceuticals – here’s what investors need to know
Johnson & Johnson announced this morning that they have entered a “definitive agreement” to acquire Momenta Pharmaceuticals at $52.50 per share. The acquisition has been confirmed as an all-cash transaction, which has been approved “unanimously” by the Board of Directors from both J&J and Momenta. The acquisition is set to be finalised later this year, […]
After rising 50% on Friday is Mesoblast now a good investment ahead of COVID-19 trials?
Mesoblast (ASX: MSB) (NASDAQ: MESO) was on our portfolio since May. However, volume started to climb higher this week as an advisory committee voted in favour of Mesoblasts pediatric drug remestemcel-L (Rynocil). The positive catalyst triggered a Mesoblast buying party on the ASX and the NASDAQ. For now, investors are optimistic about Mesoblast’s medium-long term […]
CureVac the newest vaccine contender on Wallstreet – here’s everything you need to know
CureVac’s (NASDAQ:CVAC) initial public offering in the US markets went incredibly well for investors, posting a 250% gain on its first day of trading. CureVac is a German Biopharma, based in Tübingen who specialises in the development of vaccines for infectious diseases. CVAC’s IPO raised $213.3 million USD in funding at its short price of […]
U.S government orders 100 million doses of Moderna’s vaccine, yet insiders are selling – here’s what you need to know
Moderna (NASDAQ: MRNA), alongside Novavax, is running at full speed in the vaccine race. The Trump Administration’s recent agreement with Moderna to order 100 million doses adds to the argument that MRNA is at the front of the pack. While the announcement is a positive catalyst, investors are doubtful that we will see an enormous […]
INO falls 8% ahead of today’s earnings – does YIG see value?
Inovio Pharmaceuticals (NASDAQ: INO) is probably the most controversial COVID-19 play of 2020. Some investors are incredibly bullish on the vaccine frontrunner claiming the stock will be near Novavax very soon. However, many investors are pessimistic about INO, claiming it is a COVID-19 star fizzling out. Initially, the bulls seemed to be right as INO […]